LuckyLinda
08-07-2012, 01:34 PM
Does anyone know anything about NCI trial CDR0000562261? Has anyone participated? The objective of this trial is:
To determine if the GP2 peptide/GM-CSF vaccine reduces the recurrence rate in HLA-A2-positive, HER2/neu-positive, node-positive, or high-risk node-negative breast cancer patients randomized to receive the vaccine versus the immunoadjuvant, sargramostim (GM-CSF), alone.
To determine if the AE37 peptide/GM-CSF vaccine reduces the recurrence rate in HLA-A2-negative, HER2/neu-positive, node-positive or high-risk node-negative breast cancer patients randomized to receive the vaccine versus the immunoadjuvant, GM-CSF, alone.
I am trying to be proactive. I finished 28 rads almost a week ago (ouch) and will finish Herceptin on 12/28/12.
I am attaching the link:
http://www.cancer.gov/clinicaltrials/search/view?cdrid=562261&version=healthprofessional
To determine if the GP2 peptide/GM-CSF vaccine reduces the recurrence rate in HLA-A2-positive, HER2/neu-positive, node-positive, or high-risk node-negative breast cancer patients randomized to receive the vaccine versus the immunoadjuvant, sargramostim (GM-CSF), alone.
To determine if the AE37 peptide/GM-CSF vaccine reduces the recurrence rate in HLA-A2-negative, HER2/neu-positive, node-positive or high-risk node-negative breast cancer patients randomized to receive the vaccine versus the immunoadjuvant, GM-CSF, alone.
I am trying to be proactive. I finished 28 rads almost a week ago (ouch) and will finish Herceptin on 12/28/12.
I am attaching the link:
http://www.cancer.gov/clinicaltrials/search/view?cdrid=562261&version=healthprofessional